179 related articles for article (PubMed ID: 23994886)
1. A pan-inhibitor of DASH family enzymes induces immune-mediated regression of murine sarcoma and is a potent adjuvant to dendritic cell vaccination and adoptive T-cell therapy.
Duncan BB; Highfill SL; Qin H; Bouchkouj N; Larabee S; Zhao P; Woznica I; Liu Y; Li Y; Wu W; Lai JH; Jones B; Mackall CL; Bachovchin WW; Fry TJ
J Immunother; 2013 Oct; 36(8):400-11. PubMed ID: 23994886
[TBL] [Abstract][Full Text] [Related]
2. A pan inhibitor of DASH family enzymes induces immunogenic modulation and sensitizes murine and human carcinoma cells to antigen-specific cytotoxic T lymphocyte killing: implications for combination therapy with cancer vaccines.
Donahue RN; Duncan BB; Fry TJ; Jones B; Bachovchin WW; Kiritsy CP; Lai JH; Wu W; Zhao P; Liu Y; Tsang KY; Hodge JW
Vaccine; 2014 May; 32(26):3223-31. PubMed ID: 24731809
[TBL] [Abstract][Full Text] [Related]
3. Murine rhabdomyosarcoma is immunogenic and responsive to T-cell-based immunotherapy.
Meadors JL; Cui Y; Chen QR; Song YK; Khan J; Merlino G; Tsokos M; Orentas RJ; Mackall CL
Pediatr Blood Cancer; 2011 Dec; 57(6):921-9. PubMed ID: 21462302
[TBL] [Abstract][Full Text] [Related]
4. Val-boroPro accelerates T cell priming via modulation of dendritic cell trafficking resulting in complete regression of established murine tumors.
Walsh MP; Duncan B; Larabee S; Krauss A; Davis JP; Cui Y; Kim SY; Guimond M; Bachovchin W; Fry TJ
PLoS One; 2013; 8(3):e58860. PubMed ID: 23554941
[TBL] [Abstract][Full Text] [Related]
5. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
6. Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour.
Song S; Zhang K; You H; Wang J; Wang Z; Yan C; Liu F
Clin Exp Immunol; 2010 Oct; 162(1):75-83. PubMed ID: 20735440
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas.
Merchant MS; Bernstein D; Amoako M; Baird K; Fleisher TA; Morre M; Steinberg SM; Sabatino M; Stroncek DF; Venkatasan AM; Wood BJ; Wright M; Zhang H; Mackall CL
Clin Cancer Res; 2016 Jul; 22(13):3182-91. PubMed ID: 26823601
[TBL] [Abstract][Full Text] [Related]
8. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.
Gatza E; Okada CY
J Immunol; 2002 Nov; 169(9):5227-35. PubMed ID: 12391241
[TBL] [Abstract][Full Text] [Related]
9. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
[TBL] [Abstract][Full Text] [Related]
10. Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication.
Zom GG; Willems MMJHP; Khan S; van der Sluis TC; Kleinovink JW; Camps MGM; van der Marel GA; Filippov DV; Melief CJM; Ossendorp F
J Immunother Cancer; 2018 Dec; 6(1):146. PubMed ID: 30541631
[TBL] [Abstract][Full Text] [Related]
11. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.
Duewell P; Kisser U; Heckelsmiller K; Hoves S; Stoitzner P; Koernig S; Morelli AB; Clausen BE; Dauer M; Eigler A; Anz D; Bourquin C; Maraskovsky E; Endres S; Schnurr M
J Immunol; 2011 Jul; 187(1):55-63. PubMed ID: 21613613
[TBL] [Abstract][Full Text] [Related]
12. Tumor ablation plus co-administration of CpG and saponin adjuvants affects IL-1 production and multifunctional T cell numbers in tumor draining lymph nodes.
Raaijmakers TK; van den Bijgaart RJE; den Brok MH; Wassink M; de Graaf A; Wagenaars JA; Nierkens S; Ansems M; Scheffer GJ; Adema GJ
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461350
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.
Morisaki T; Matsumoto K; Onishi H; Kuroki H; Baba E; Tasaki A; Kubo M; Nakamura M; Inaba S; Yamaguchi K; Tanaka M; Katano M
Hum Cell; 2003 Dec; 16(4):175-82. PubMed ID: 15147037
[TBL] [Abstract][Full Text] [Related]
14. Myeloid-derived Suppressor Cells Elimination by 5-Fluorouracil Increased Dendritic Cell-based Vaccine Function and Improved Immunity in Tumor Mice.
Khosravianfar N; Hadjati J; Namdar A; Boghozian R; Hafezi M; Ashourpour M; Kheshtchin N; Banitalebi M; Mirzaei R; Razavi SA
Iran J Allergy Asthma Immunol; 2018 Feb; 17(1):47-55. PubMed ID: 29512369
[TBL] [Abstract][Full Text] [Related]
15. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
Timmerman JM; Levy R
J Immunol; 2000 May; 164(9):4797-803. PubMed ID: 10779787
[TBL] [Abstract][Full Text] [Related]
16. The optimal interval for dendritic cell vaccination following adoptive T cell transfer is important for boosting potent anti-tumor immunity.
Park MY; Kim CH; Sohn HJ; Oh ST; Kim SG; Kim TG
Vaccine; 2007 Oct; 25(42):7322-30. PubMed ID: 17889413
[TBL] [Abstract][Full Text] [Related]
17. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity.
Prins RM; Craft N; Bruhn KW; Khan-Farooqi H; Koya RC; Stripecke R; Miller JF; Liau LM
J Immunol; 2006 Jan; 176(1):157-64. PubMed ID: 16365406
[TBL] [Abstract][Full Text] [Related]
18. Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways.
Kuwashima N; Nishimura F; Eguchi J; Sato H; Hatano M; Tsugawa T; Sakaida T; Dusak JE; Fellows-Mayle WK; Papworth GD; Watkins SC; Gambotto A; Pollack IF; Storkus WJ; Okada H
J Immunol; 2005 Aug; 175(4):2730-40. PubMed ID: 16081851
[TBL] [Abstract][Full Text] [Related]
19. Efficient eradication of subcutaneous but not of autochthonous gastric tumors by adoptive T cell transfer in an SV40 T antigen mouse model.
Bourquin C; von der Borch P; Zoglmeier C; Anz D; Sandholzer N; Suhartha N; Wurzenberger C; Denzel A; Kammerer R; Zimmermann W; Endres S
J Immunol; 2010 Aug; 185(4):2580-8. PubMed ID: 20644173
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant.
Fernández A; Mesa C; Marigo I; Dolcetti L; Clavell M; Oliver L; Fernández LE; Bronte V
J Immunol; 2011 Jan; 186(1):264-74. PubMed ID: 21135171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
